Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer

Shanon Lacy, Antonio Lopez-Beltran, Gregory T. MacLennan, Stephanie R. Foster, Rodolfo Montironi, Liang Cheng

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Bladder cancer remains one of the most common and expensive cancers to treat worldwide. Numerous molecular markers are being investigated as possible ways to decrease health care costs, increase patient survival and prognosis, and increase sensitivity in screening tests. Several genetic markers have emerged as potential therapeutic targets and have provided new theories concerning the origins and progression of these tumors. Future classifications of bladder tumors should be based on the understanding of disease processes and should incorporate these emerging biomarkers for stratification of tumors into different prognostic groups.

Original languageEnglish
Pages (from-to)5-16
Number of pages12
JournalAnalytical and Quantitative Cytology and Histology
Volume31
Issue number1
StatePublished - Feb 2009

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Carcinoma
Tumor Biomarkers
Genetic Markers
Health Care Costs
Neoplasms
Survival
Therapeutics

Keywords

  • Biomarkers
  • Bladder cancer
  • Molecular genetics

ASJC Scopus subject areas

  • Anatomy
  • Histology

Cite this

Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer. / Lacy, Shanon; Lopez-Beltran, Antonio; MacLennan, Gregory T.; Foster, Stephanie R.; Montironi, Rodolfo; Cheng, Liang.

In: Analytical and Quantitative Cytology and Histology, Vol. 31, No. 1, 02.2009, p. 5-16.

Research output: Contribution to journalArticle

Lacy, Shanon ; Lopez-Beltran, Antonio ; MacLennan, Gregory T. ; Foster, Stephanie R. ; Montironi, Rodolfo ; Cheng, Liang. / Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer. In: Analytical and Quantitative Cytology and Histology. 2009 ; Vol. 31, No. 1. pp. 5-16.
@article{26d53238c45a44bebdd746445c0bc974,
title = "Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer",
abstract = "Bladder cancer remains one of the most common and expensive cancers to treat worldwide. Numerous molecular markers are being investigated as possible ways to decrease health care costs, increase patient survival and prognosis, and increase sensitivity in screening tests. Several genetic markers have emerged as potential therapeutic targets and have provided new theories concerning the origins and progression of these tumors. Future classifications of bladder tumors should be based on the understanding of disease processes and should incorporate these emerging biomarkers for stratification of tumors into different prognostic groups.",
keywords = "Biomarkers, Bladder cancer, Molecular genetics",
author = "Shanon Lacy and Antonio Lopez-Beltran and MacLennan, {Gregory T.} and Foster, {Stephanie R.} and Rodolfo Montironi and Liang Cheng",
year = "2009",
month = "2",
language = "English",
volume = "31",
pages = "5--16",
journal = "Analytical and Quantitative Cytopathology and Histopathology",
issn = "0301-102X",
publisher = "John Rylands University Library",
number = "1",

}

TY - JOUR

T1 - Molecular pathogenesis of urothelial carcinoma the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer

AU - Lacy, Shanon

AU - Lopez-Beltran, Antonio

AU - MacLennan, Gregory T.

AU - Foster, Stephanie R.

AU - Montironi, Rodolfo

AU - Cheng, Liang

PY - 2009/2

Y1 - 2009/2

N2 - Bladder cancer remains one of the most common and expensive cancers to treat worldwide. Numerous molecular markers are being investigated as possible ways to decrease health care costs, increase patient survival and prognosis, and increase sensitivity in screening tests. Several genetic markers have emerged as potential therapeutic targets and have provided new theories concerning the origins and progression of these tumors. Future classifications of bladder tumors should be based on the understanding of disease processes and should incorporate these emerging biomarkers for stratification of tumors into different prognostic groups.

AB - Bladder cancer remains one of the most common and expensive cancers to treat worldwide. Numerous molecular markers are being investigated as possible ways to decrease health care costs, increase patient survival and prognosis, and increase sensitivity in screening tests. Several genetic markers have emerged as potential therapeutic targets and have provided new theories concerning the origins and progression of these tumors. Future classifications of bladder tumors should be based on the understanding of disease processes and should incorporate these emerging biomarkers for stratification of tumors into different prognostic groups.

KW - Biomarkers

KW - Bladder cancer

KW - Molecular genetics

UR - http://www.scopus.com/inward/record.url?scp=61849133968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849133968&partnerID=8YFLogxK

M3 - Article

C2 - 19320188

AN - SCOPUS:61849133968

VL - 31

SP - 5

EP - 16

JO - Analytical and Quantitative Cytopathology and Histopathology

JF - Analytical and Quantitative Cytopathology and Histopathology

SN - 0301-102X

IS - 1

ER -